Insight Molecular Diagnostics IMDX Cash Flow Statement (2015-2026)

NASDAQ IMDX
$4.27 -0.03 (-0.70%)
As of: Aug 27, 2026 · 3:59 PM EDT
Reported Financials

Insight Molecular Diagnostics Quarterly Cash Flow Statement

Periods 46 quarters
Latest Jun 2026

Insight Molecular Diagnostics reported cash from operations of -$9.27M and free cash flow of -$10.05M for the quarter ended Jun 2026, down 50.1% year over year. This cash flow statement covers 46 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-13.80M-35.69M-10.29M-8.30M-9.33M-44.98M3.03M-8.33M-6.49M-15.99M-9.13M-4.95M-13.52M-20.89M-6.80M-9.84M-11.05M-12.89M-9.09M-11.40M
Share-based CompensationStock Comp.
10.64M1.08M21.00M21.00M21.00M2.62M21.00M1.05M1.05M0.48M0.52M0.77M0.85M0.50M1.11M1.82M2.36M0.72M5.20M5.30M
Deferred Taxes
0.10M
Gains from Investment SecuritiesGains Investment
1.17M-27.33M-4.66M-6.36M-6.14M-13.86M-18.31M1.79M-0.43M11.19M3.31M-1.03M7.14M-13.70M0.88M2.80M3.38M-1.11M-5.92M2.28M
Asset Writedowns and ImpairmentWritedown
5.00M-0.05M1.81M-0.00M36.90M
Cash from OperationsCash from Ops.
-10.98M-7.07M-13.28M-11.25M-11.40M-9.65M-8.30M-6.83M-3.77M-4.42M-3.83M-5.98M-5.53M-5.35M-5.84M-6.17M-4.63M-5.54M-7.64M-9.27M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.01M0.01M0.01M0.00M0.00M
Depreciation & Amortization (CF)Dep. & Amort.
0.26M0.22M0.29M0.38M0.39M0.40M0.45M0.43M0.40M0.30M0.31M0.30M0.32M0.63M0.49M0.56M0.58M0.57M0.63M0.67M
Change in Working Capital
Change in ReceivablesChange Receivables
0.01M0.41M0.69M-0.32M0.19M0.02M-0.11M-0.18M0.17M0.02M-0.32M-0.08M0.12M1.40M1.93M-3.03M-0.25M0.87M-0.97M0.04M
Change in InventoryChange Inventory
0.23M0.18M0.05M0.23M-0.22M-0.03M-0.06M-0.17M
Change in Account PayablesChange Payables
Change in Accured ExpensesChange Accured Exp.
-0.83M0.24M-0.02M0.26M0.18M-0.12M-2.66M-1.66M0.13M-0.56M0.85M-1.24M0.65M0.70M1.03M-3.11M1.18M3.56M-0.10M-1.10M
Investing Activities
Capital ExpendituresCapex
0.39M0.40M1.56M1.12M0.86M0.80M-0.56M0.26M0.02M0.19M0.09M0.21M0.31M0.35M1.05M1.48M0.61M0.78M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.23M
Acquisitions
Change in Acquisitions & DivestmentsChange Acquisitions
Cash from Investing ActivitiesCash from Investing
-0.39M-0.40M-1.56M-1.12M-0.86M-0.80M-1.37M0.12M0.21M0.10M-0.02M-0.19M-0.09M-0.21M-0.31M-0.35M-1.05M-1.48M-0.61M-0.78M
Financing Activities
Other financing activitiesOther financing
1.03M0.03M
Cash from Financing ActivitiesCash from Financing
8.21M-0.27M-0.35M36.79M-0.53M-0.10M-0.03M12.27M-0.03M-0.03M9.85M-0.26M10.84M28.56M-0.11M-0.12M-0.25M24.70M-0.56M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
5.62M3.16M6.48M0.14M0.35M0.60M0.02M1.31M0.00M
Net Equity Issued and RepurchasedNet Equity Issued
0.00M5.00M15.81M10.21M29.14M26.02M
Additional items
Exchange Rate EffectFX Effect
-0.00M-0.02M-0.10M0.02M-0.01M-0.01M-0.02M
Change in Cash
-3.16M-7.74M-15.21M24.45M-12.78M-10.55M-9.70M5.57M-3.58M-4.35M-3.85M3.68M-5.89M5.27M22.39M-6.74M-5.78M-7.29M16.44M-10.63M
Free Cash FlowFCF
-11.38M-7.47M-14.84M-12.37M-12.26M-10.45M-8.30M-6.83M-3.21M-4.69M-3.85M-6.17M-5.62M-5.57M-6.15M-6.52M-5.68M-7.02M-8.25M-10.05M
Net Cash FlowNCF
-3.16M-7.74M-15.19M24.42M-12.78M-10.55M-9.70M5.57M-3.58M-4.35M-3.85M3.68M-5.87M5.28M22.41M-6.64M-5.80M-7.28M16.45M-10.61M